Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
39.84 USD | -0.38% | +4.87% | +54.60% |
05-31 | Citigroup Downgrades Calliditas Therapeutics to Neutral From Buy, Price Target at $39 | MT |
05-31 | Calliditas Partner Secures European Panel Backing for Rare Kidney Disease Treatment | MT |
Turnover - Change in analysts' estimates
Earnings Per Share (EPS) - Change in analysts' estimates
EBIT - Change in analysts' estimates
Dividend / Share (DPS) - Change in analysts' estimates
Cash or Net Debt - Change in analysts' estimates
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Equities
- CALTX Stock
- CALT Stock
- Revisions Calliditas Therapeutics AB